China Medical System Holdings Ltd. Announces Interim Dividend for the Six Months Ended June 30, 2013, Payable on August 30, 2013; Announces Executive Changes; Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2013
August 06, 2013 at 12:06 pm EDT
Share
China Medical System Holdings Ltd. has resolved to pay an interim dividend of $0.00838 (equivalent to HKD 0.065) per ordinary share of the Company for the six months ended 30 June 2013 to the shareholders whose names appear on the register of members of the Company at the close of business on 23 August 2013. Payment of such interim dividend is expected to be made to the shareholders on 30 August 2013.
The Board announced that Mr. Hui Vincent Wing Sin has tendered his resignation as the company secretary of the Company, an authorized representative of the Company as required under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the authorized representative in Hong Kong to accept service of process and notices on behalf of the Company as required under Rule 19.05(2) of the Listing Rules and Part XI of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong) with effect from 6 August 2013, due to his other personal commitments. Mr. Hui confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company. The Board also announced that following Mr. Hui's resignation, Ms. Zhang Lingyan (Ms. Zhang') has been appointed as the company secretary, an authorized representative of the Company as required under Rule 3.05 of the Listing Rules and the authorized representative in Hong Kong to accept service of process and notices on behalf of the Company as required under Rule 19.05(2) of the Listing Rules and Part XI of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong) with effect from 6 August 2013. Ms. Zhang joined the Group in July 2000 and currently holds the positions of director of Legal and Investment Affairs of the Group and director of the CEO's office. Ms. Zhang is primarily responsible for overseeing the legal and investment affairs of the Group, including compliance with the Listing Rules.
The company reported unaudited consolidated earnings results for the six months ended June 30, 2013. For the period, the company reported turnover of $166.995 million compared to $132.039 million a year ago. Profit before taxation was $55.498 million compared to $46.709 million a year ago. Profit attributable to owners of the company of $50.490 million or 2.091 cents per diluted share compared to $41.267 million or 1.709 cents per diluted share a year ago.
China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.
China Medical System Holdings Ltd. Announces Interim Dividend for the Six Months Ended June 30, 2013, Payable on August 30, 2013; Announces Executive Changes; Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2013